ARVN Jul 2024 50.000 put
| Previous close | 9.70 |
| Open | 9.70 |
| Bid | 11.10 |
| Ask | 15.20 |
| Strike | 50.00 |
| Expiry date | 2024-07-19 |
| Day's range | 9.70 - 9.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireArvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6 in New York City. John Houston, Ph.D., Chairperson, Chief Executive Officer and President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will participate
- GlobeNewswire
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congre
Simply Wall St.It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Arvinas' Annual General Meeting to take place on 29th of May CEO John Houston's total compensation...
